Carotid stenting with embolic protection: evolutionary advances.
Stroke is one of the most significant causes of death and morbidity worldwide. Atherosclerotic stenosis of the extracranial internal carotid artery has been invoked as a common causative factor for stroke in over 20% of patients. Although medical therapy can help to prevent the onset and progression of carotid arteriosclerosis, open surgical carotid endarterectomy has been the gold standard for treating severe blockage. Carotid artery stenting has recently demonstrated efficacy in stroke prevention from atherosclerosis, and in high-risk surgical subgroups, has been shown to be associated with a reduction in the risk of myocardial infarction. The controversy for carotid stenting surrounds the incidence of periprocedural stroke. Will embolic protection devices (EPDs) decrease this risk? EPDs continue to evolve with various engineering strategies directed at increasing the efficiency of protection. There are two major categories of EPDs: distal occlusion, either with balloons (e.g., Percusurge, Medtronic Corporation, MN, USA); or distal filtration (e.g., Angioguard, Cordis Corporation, NJ, USA). The second method is proximal protection (e.g., MoMA device, Invatec Corporation, Brescia, Italy). We review the results of trials currently evaluating carotid stenting with both distal and proximal embolic protection.